Long-term results of a prospective trial of mantle irradiation alone for early-stage Hodgkin's disease

Annals of Oncology

Volumn 17, Issue 11, 2006, Pages 1693-1697

  Ng, A K ^a   Li, S ^b   Neuberg, D ^b   Fisher, D C ^b   McMillan, C ^a   Silver, B ^a   Marcus, K C ^c   Stevenson, M A ^d   Mauch, P M ^a,e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e NONE   (United States)

Author keywords

Hodgkin's disease; Late effects; Radiation therapy

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; TAMOXIFEN; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CALCULATION; CANCER MORTALITY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CAUSE OF DEATH; CLINICAL TRIAL; EARLY CANCER; ENDOMETRIUM CARCINOMA; FEMALE; FOLLOW UP; HEART INFARCTION; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; KAPLAN MEIER METHOD; LONG TERM CARE; LUNG HILUS; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MANTLE FIELD RADIOTHERAPY; MEDIASTINUM LYMPH NODE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PAGET NIPPLE DISEASE; PATIENT SELECTION; PRIORITY JOURNAL; RADIATION DOSE; SALVAGE THERAPY; SCHOOL CHILD; STATISTICAL ANALYSIS; SURVIVAL RATE; SYMPTOMATOLOGY; TREATMENT FAILURE;

ADOLESCENT; ADULT; CHILD; FEMALE; HODGKIN DISEASE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RECURRENCE; SALVAGE THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 33750580068     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl288     Document Type: Article

References (24)

1. Tubiana M, Amiel JL, Hayat M et al. Current trend in the treatment of Hodgkin's disease. Radiat Med 1983; 1: 221-229.
2. Hoppe RT. Stage I-II Hodgkin's disease: Current therapeutic options and recommendations. Blood 1983; 62: 32-36.
3. Leslie NT, Mauch PM, Hellman S. Stage IA to IIB supradiaphragmatic Hodgkin's disease. Long-term survival and relapse frequency. Cancer 1985; 55: 2072-2078.
4. Mauch P, Tarbell N, Weinstein H et al. Stage IA and IIA supradiaphragmatic Hodgkin's disease: Prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. J Clin Oncol 1988; 6: 1576-1583.
5. Tubiana M, Henry-Amar M, Carde P et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood 1989; 73: 47-56.
6. Backstrand KH, Ng AK, Takvorian RW et al. Results of a prospective trial of mantle irradiation alone for selected patients with early-stage Hodgkin's disease. J Clin Oncol 2001; 19: 736-741.
7. Gray R. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
8. Liao Z, Ha CS, Vlachaki MT et al. Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: Long-term follow-up and patterns of failure. Int J Radiat Oncol Biol Phys 2001; 50: 971-977.
9. Hennequin C, Carrie C, Hofstetter S et al. A quality control program for radiotherapy in Hodgkin's disease. Cancer Radiother 1999; 3: 187-190.
10. Dieckmann K, Potter R, Wagner W et al. Up-front centralized data review and individualized treatment proposals in a multicenter pediatric Hodgkin's disease trial with 71 participating hospitals: The experience of the German-Austrian pediatric multicenter trial DAL-HD-90. Radiother Oncol 2002; 62: 191-200.
11. Eich HT, Staar S, Gossmann A et al. Centralized radiation oncologic review of cross-sectional imaging of Hodgkin's disease leads to significant changes in required involved field-results of a quality assurance program of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 2004; 58: 1121-1127.
12. Eich HT, Muller RP, Schneeweiss A et al. Initiation of a teleradiotherapeutic network for patients in German lymphoma studies. Int J Radiat Oncol Biol Phys 2004; 58: 805-808.
13. Eich HT, Staar S, Gossmann A et al. The HD12 panel of the German Hodgkin Lymphoma Study Group (GHSG): A quality assurance program based on a multidisciplinary panel reviewing all patients' imaging. Am J Clin Oncol 2004; 27: 279-284.
14. Swerdlow A, Barber J, Horwich A et al. Second malignancy in patients with Hodgkin's disease treated at the Royal Marsden Hospital. Br J Cancer 1997; 75: 116-123.
15. Wirth A, Chao M, Corry J et al. Mantle irradiation alone for clinical stage I-II Hodgkin's disease: Long-term follow-up and analysis of prognostic factors in 261 patients. J Clin Oncol 1999; 17: 230-240.
16. Noordijk EM, Carde P, Hagenbeek A et al. Combination of radiotherapy is advisable in all patients with clinical stage I-II Hodgkin's disease: six-year results of EORTC-GPMC controlled clinical trials H7-VF, H7-F and H7-U. Int J Radiat Oncol Biol Phys 1997; 39: 173a (Abstr 77).
17. Partridge S, Timothy A, O'Doherty MJ et al. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin's disease: Influence on patient management in a single institution. Ann Oncol 2000; 11: 1273-1279.
18. Friedberg JW, Fischman A, Neuberg D et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: A blinded comparison. Leuk Lymphoma 2004; 45: 85-92.
19. Rini JN, Nunez R, Nichols K et al. Coincidence-detection FDG-PET versus gallium in children and young adults with newly diagnosed Hodgkin's disease. Pediatr Radiol 2005; 35: 169-178.
20. Lin P, Chu J, Kneebone A et al. Direct comparison of 18F-fluorodeoxyglucose coincidence gamma camera tomography with gallium scanning for the staging of lymphoma. Intern Med J 2005; 35: 91-96.
21. Hagenbeek A, Eghbali H, Fermé C et al. Three cycles of MOPP/ABV hybrid and involved-field irradiation is more effective than subtotal nodal irradiation in favorable supradiaphragmatic clinical stages I-II Hodgkin's disease: Preliminary results of the EORTC-GELA H8-F randomized trial in 543 patients. Blood 2000; 96: 757a (Abstr 2472).
22. Press OW, LeBlanc M, Lichter AS et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 2001; 19: 4238-4244.
23. Sieber M, Franklin J, Tesch H et al. Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin's disease: Results of the German Hodgkin's Lymphoma Study Group (GHSG) Trial HD7. Blood 2002; 100: 341a (Abstr 341).
24. Radford JA, Williams MV, Hancock BW et al. Minimal initial chemotherapy plus involved field radiotherapy (RT) vs. mantle field RT for clinical stage IA/IIA supradiaphragmatic Hodgkin's disease (HD). Results of the UK Lymphoma Group LY07 Trial. Eur J Haematol 2004; 73: E08a (Abstr E08).